Neuroblastoma (NB)Early Phase 1NCT07767630
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
A Early Phase 1 study testing [211At]MABG in people with Neuroblastoma (NB), run by Sichuan University at 1 site in China.
Trial summary
Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma Read more about this study
- Who is it for?
- Ages 1 year to 100 years
- Conditions the study is for
- Neuroblastoma (NB)
- What is being tested?
- [211At]MABG
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteChina
- Study dates
- 21 Jul 2026to 30 Jun 2027
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 100 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients diagnosed with MIBG avid lesions, high-risk neuroblastoma per the Revised International Neuroblastoma Response Criteria (Revised INRC), with refractory, relapsed, or progressive disease.
- All measurable soft tissue lesions must be MIBG-avid.
- Age ≥ 1 year at enrollment.
- Lansky performance status ≥ 50%.
- Adequate organ function and hematologic parameters.
Who cannot join
- Antibody-based immunotherapy within fewer than 5 half-lives or 30 days (whichever is shorter), or who have not yet recovered from adverse effects of any biologic therapy.
- Treatment with [¹³¹I]MIBG or Lu177 targeted radionuclide therapy less than 3 months of last administration.
- Autologous stem cell transplant <12 weeks, or Allogeneic stem cell transplant <4 months (patients >4 months post-transplant must be free of active GVHD).
- Radiotherapy within 2 weeks prior to the first study dose (However, patients with a single-site irradiation that remains MIBG avid may be enrolled.) or extensive-field radiotherapy (e.g., craniospinal, whole abdomen, whole lung, or >50% of bone marrow area) within 12 weeks prior to the first study dose.
- Renal Insufficiency.
- Active Infections.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
West China Hospital
Chengdu, Sichuan, 000000
Rong TIAN, +86 189 8060 1586, rongtiannuclear@126.com
About this study
Official title: An Exploratory Proof-of-Concept (POC) Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Fractionated Dosing of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma (Including a Run-in Phase)
Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
Read the detailed description
Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
- Conditions
- Neuroblastoma (NB)
- Being tested
- [211At]MABG
- Keywords
- Radiopharmaceutical
- Medical subject headings
- Neuroblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
[211At]MABGDrug
Fractionated Dose
| Study group | Role | What they receive |
|---|---|---|
| [211At]MABG | Experimental | Fractionated Dose Receives: Drug: [211At]MABG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and severity of dose-limiting toxicities (DLTs)
Incidence and severity of dose-limiting toxicities (DLTs)
Measured: From administration of [211At]MABG until 4 weeks after injection
Incidence and severity of adverse events (AEs) as assessed by CTCAE v5.0
Incidence and severity of adverse events (AEs) as assessed by CTCAE v5.0
Measured: From administration of [211At]MABG until 4 weeks after last dose of injection
Secondary outcomes (2)
Response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC)
Response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC)
Measured: 8 weeks after [211At]MABG administration, Participants without disease progression (PD) will be evaluated every 8 weeks for the first 24 weeks, then every 12 weeks until PD, new cancer therapy, death, or study termination
Absorbed radiation dose (Gy) distribution in normal organs and tumors by quantitative SPECT/CT dosimetry
Absorbed radiation dose (Gy) distribution in normal organs and tumors by quantitative SPECT/CT dosimetry
Measured: About 21hours from time of [211At]MABG administration]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2026
- Study start21 Jul 2026
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuroblastoma (NB)Studies of the same condition, open and under way.
- More trials run by Sichuan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sichuan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rong Tian, Sichuan University
- Investigators
- Rong TIAN, MD, Principal investigator, West China Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07767630
- Sponsor's protocol ID
- HX2602
- Status last verified
- Aug 2026
- First submitted
- 12 Aug 2026
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Exploratory Proof-of-Concept (POC) Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Fractionated Dosing of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma (Including a Run-in Phase)
- ClinicalTrials.gov ID
- NCT07767630
- Acronym / sponsor ID
- HX2602
- Conditions
- Neuroblastoma (NB)
- Keywords
- Radiopharmaceutical
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Sichuan UniversityUniversity, hospital or other
- Study start
- 21 Jul 2026 (actual)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 17 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
Detailed description
Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| [211At]MABG | Experimental | Drug: [211At]MABGFractionated Dose |
Who may qualify
- Ages
- 1 year to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Patients diagnosed with MIBG avid lesions, high-risk neuroblastoma per the Revised International Neuroblastoma Response Criteria (Revised INRC), with refractory, relapsed, or progressive disease.
- All measurable soft tissue lesions must be MIBG-avid.
- Age ≥ 1 year at enrollment.
- Lansky performance status ≥ 50%.
- Adequate organ function and hematologic parameters.
Key exclusion criteria (6 listed)
- Antibody-based immunotherapy within fewer than 5 half-lives or 30 days (whichever is shorter), or who have not yet recovered from adverse effects of any biologic therapy.
- Treatment with [¹³¹I]MIBG or Lu177 targeted radionuclide therapy less than 3 months of last administration.
- Autologous stem cell transplant <12 weeks, or Allogeneic stem cell transplant <4 months (patients >4 months post-transplant must be free of active GVHD).
- Radiotherapy within 2 weeks prior to the first study dose (However, patients with a single-site irradiation that remains MIBG avid may be enrolled.) or extensive-field radiotherapy (e.g., craniospinal, whole abdomen, whole lung, or >50% of bone marrow area) within 12 weeks prior to the first study dose.
- Renal Insufficiency.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| [211At]MABGFractionated Dose | Drug | [211At]MABG |
Primary outcome
Incidence and severity of dose-limiting toxicities (DLTs)
Time frame: From administration of [211At]MABG until 4 weeks after injection
Incidence and severity of dose-limiting toxicities (DLTs)
Incidence and severity of adverse events (AEs) as assessed by CTCAE v5.0
Time frame: From administration of [211At]MABG until 4 weeks after last dose of injection
Incidence and severity of adverse events (AEs) as assessed by CTCAE v5.0
2 secondary outcomes
Response assessed in accordance with the Revised International Neuroblastoma Response Criteria (INRC)
Time frame: 8 weeks after [211At]MABG administration, Participants without disease progression (PD) will be evaluated every 8 weeks for the first 24 weeks, then every 12 weeks until PD, new cancer therapy, death, or study termination
Absorbed radiation dose (Gy) distribution in normal organs and tumors by quantitative SPECT/CT dosimetry
Time frame: About 21hours from time of [211At]MABG administration]
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
Related trials for Neuroblastoma (NB)
RecruitingPhase 2
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
Neuroblastoma, High-risk Neuroblastoma
RecruitingPhase 2
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
Neuroblastoma (NB), Neuroblastoma in Children
Active, not recruitingEarly Phase 1
A Study of N9 Chemotherapy in Children With Neuroblastoma
Neuroblastoma, Pediatric Cancer
Active, not recruitingEarly Phase 1
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Neuroblastoma (NB)
RecruitingPhase 3
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB), Ganglioneuroblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Rong TIAN, MD principal investigator
West China Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing [211At]MABG in people with Neuroblastoma (NB), run by Sichuan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rong TIAN, MD (+86 189 8060 1586, rongtiannuclear@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence and severity of dose-limiting toxicities (DLTs) (time frame: From administration of [211At]MABG until 4 weeks after injection). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026.